Marker patterns of other AML-related differentiation: Difference between revisions
From haematologyetc.co.uk
(Created page with "---- <div style="width: 200px"> {| class="wikitable" style="border-left:solid 5px green;border-right:solid 5px green;border-top:solid 5px black;border-bottom:solid 5px black; font-size:90%; color:navy" | colspan="1"''|Return to previous page'' |} </div> ---- ''These markers are not considered to define myeloid lineage, and generally have lower lineage specificity than myeloid-lineage associated markers, however they can support c...") |
No edit summary |
||
Line 7: | Line 7: | ||
---- | ---- | ||
<div style="width: 95%"> | <div style="width: 95%"> |
Revision as of 19:25, 30 January 2024
Markers associated with erythroid differentiation in AML | |
---|---|
Most often AML with erythroid maturation will express CD34, while CD45 and HLA-DR are weak or negative. CD117 is generally expressed. There may be some expression of megkaryocytic markers in some cases. | |
CD36 | Expression is expected, but often expressed in other subtypes so not fully lineage specific |
CD71 | Frequently expressed though not fully lineage specific |
CD235 | A good marker of erythroid differentiation but acquired late and therefore may not be expressed
|
Markers associated with megakaryocytic differentiation in AML | |
---|---|
Most often CD34, CD45 and HLA-DR are weak or negative, although CD13 and CD33 may be expressed | |
CD41 | Platelet glycoprotein IIbIIIa |
CD61 | Platelet glycoprotein IIIa |
CD36 | Relatively non-specific (seen in erythroid and monocytic leukaemias) but often strongly expressed
|